Strategic Cooperation between Baitu Biotech and Sanofi: Focusing on AI Models in the Field of Life Sciences

Global Network Technology Comprehensive ReportOn October 11th, it was announced that Biotech announced a strategic partnership with Sanofi to jointly develop a model for the discovery of biological therapy drugs based on the Biotech Life Sciences model.With the customized basic models and artificial intelligence expertise of Baitu Biotech, as well as Sanofi's proprietary data, protein engineering innovation, and biological agent development experience, both parties aim to create leading protein big language models and artificial intelligence task models to achieve biological agent design and multi-parameter optimization

Global Network Technology Comprehensive ReportOn October 11th, it was announced that Biotech announced a strategic partnership with Sanofi to jointly develop a model for the discovery of biological therapy drugs based on the Biotech Life Sciences model.

With the customized basic models and artificial intelligence expertise of Baitu Biotech, as well as Sanofi's proprietary data, protein engineering innovation, and biological agent development experience, both parties aim to create leading protein big language models and artificial intelligence task models to achieve biological agent design and multi-parameter optimization.

According to the terms of the agreement, Baitu Biotech will receive a prepayment of $10 million in cash from Sanofi, as well as multiple recent model development payments, research and development milestone payments, sales milestone payments, and other returns, with a total transaction amount exceeding $1 billion.

Song Le, Chief Technology Officer of Baitu Biotech, stated that, This collaboration is a large-scale collaboration based on basic models in the field of life sciences. We are pleased to work with Sanofi to utilize the artificial intelligence engine of BioBiotech to solve the challenges related to new protein therapies and drive drug development. We use datasets from public and private resources to construct a basic protein biological map to guide our computational models. At the same time, we automate and integrate workflows Cheng, we have been able to achieve sustainable collection of high-quality data, thereby advancing the development of new drugs and optimizing their progress

It is reported that in the field of artificial intelligence, traditional methods require a large amount of labeled data to make accurate predictions. However, there is often a shortage of labeled data in the life sciences industry. The R&D team of Baitu Biotech is committed to revolutionizing artificial intelligence in the field of biology by training a large parameter model that uses universal unlabeled data to provide information for multiple downstream task models. This method enables multiple fields including immunology, neurology, oncology, and rare diseases to make more accurate predictions based on limited data.

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])